Profile of 刘伟生 Jeremy Low

刘伟生 Jeremy Low

合伙人 Partner , BCom LLB (Hons) LLM (Hons)

About 刘伟生 Jeremy Low

Jeremy specialises in mergers and acquisitions, corporate restructurings and foreign investment clearances.

He is highly experienced in competitive sale processes and managing consortium bids and complex transactions. He has a strong track record advising on cross-border transactions involving Chinese investors and navigating Australia's foreign investment review process. Jeremy is recognised by Chambers Global and Chambers-Asia Pacific 2018 as a notable practitioner in M&A and Life Sciences and for his expertise advising on inbound investments from China. He also leads Allens' Healthcare sector.

His private treaty M&A experience includes advising:

  • First State Super – on its successful $2.86 billion bid for a concession to operate the land titles and registry functions of Land Use Victoria for a 40 year term.
  • a consortium led by First State Super and Hastings Funds Management – on its successful A$2.6 billion bid to operate a 35-year concession of the land titling and registry operations of New South Wales Land and Property Information.
  • First Solar – on the sales of the Manildra Solar Farm and Beryl Solar Farm to ASX listed, New Energy Solar, following a competitive sale process.
  • Goldwind – on its successful bid to purchase the Stockyard Hill Wind Farm Project in Victoria, following a competitive sale process run by Origin Energy.
  • Pfizer – as Australian counsel on its on its JV with GSK to create a global consumer healthcare company, its US$17 billion acquisition of Hospira, its US$11.9 billion sale of its infant nutrition business to Nestlé, its US$68 billion acquisition of Wyeth, including the successful divestments of the Fort Dodge companion animal vaccines business to Boehringer Ingelheim and the Fort Dodge Australia livestock business to Virbac and its sale of its Australian consumer healthcare business to Johnson & Johnson.
  • Nestlé – advising on its announced review of strategic options for Nestlé Skin Health.
  • DuPont – on the Australian corporate law aspects of its merger of equals with Dow involving the spin out of three publicly traded companies, and DuPont Pioneer on the divestment of its Australian seeds production and distribution business.
  • Archer Capital – on its sale of private hospital business Healthe Care to China's Luye Medical Group for A$938 million.
  • Ingenico Group – on its acquisition of NZ EFTPOS provider Paymark from ANZ, ASB, BNZ and Westpac.
  • Allianz Australia – on its acquisition from the Northern Territory Government of its privatised general insurance business for A$424 million.
  • Beijing Capital Group – on its acquisition from Transpacific Industries Group Ltd of its integrated waste management business in New Zealand for NZ$950 million.
  • Telecom Corporation of New Zealand Limited – on the sale of AAPT Limited to TPG Telecom Limited for A$450 million.
  • Merck – as Australian counsel on its US$41 billion merger with Schering-Plough, including integration and transactions related to the merger.
  • Japan-based Nikko Asset Management Co., Ltd. – on its acquisition of Tyndall Investments in Australia and New Zealand, from the Suncorp-Metway Group.

His public M&A experience includes advising:

  • Pacific Equity Partners – in relation to the acquisition of ASX-listed LifeHealthcare Group Limited, a medical device distributor via a members’ scheme of arrangement.
  • Caisse de Depot et Placement du Quebec and Utilities Trust of Australia – on their A$1.2 billion takeover bid for Hastings Diversified Utilities Fund, an ASX listed stapled infrastructure fund.
  • St.George Bank – on its A$67 billion merger with Westpac Banking Corporation by way of scheme of arrangement.
  • Dairy Farmers – on its sale to National Foods for A$910 million by way of scheme of arrangement.
  • Wesfarmers – on its recommended cash and share offer for Coles by way of scheme of arrangement for A$20.7 billion.
  • Brambles – on the unification of its Australian/UK Dual Listed Companies structure via a 'top-hatting' scheme of arrangement.

Jeremy was based in our Shanghai office from 2002 to 2006 where he acted on a number of significant China in-bound investments including for ANZ Bank on its acquisitions of a 19.9 per cent stake in Shanghai Rural Commercial Bank (the largest rural commercial bank in China at the time) for US$252 million, and a 20 per cent stake in Bank of Tianjin (China's fourth largest city commercial bank by assets at the time) for US$120 million.

Jeremy is a co-author of the Lexis/Nexis service, Australian Corporations Practice and regularly presents on corporate governance.